Moreover, initial clinical studies reported that administration of naringenin contributed to the protection against oxidative stress and inflammation related to NAFLD through decreasing liver lipid peroxidation, increasing liver antioxidant content, and attenuating hepatic pro-inflammatory gene expression including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-1β via inhibition of NF-kB activation [21, 44–46]. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.